US2012003260A1PendingUtilityA1

Solid-Phase and Solution-Phase Synthesis of Glycosylphosphatidylinositol Glycans

46
Assignee: SEEBERGER PETER HPriority: Jul 10, 2002Filed: May 17, 2011Published: Jan 5, 2012
Est. expiryJul 10, 2022(expired)· nominal 20-yr term from priority
C07H 15/207C07H 15/203C08B 37/006A61P 33/02A61P 37/04
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

One aspect of the present invention relates to solution-phase approaches to GPI synthesis. Another aspect of the present invention relates to key building blocks, and syntheses thereof, useful for GPI assembly. Yet another aspect of the invention relates to an automated method for the synthesis of GPIs and fragments thereof.

Claims

exact text as granted — not AI-modified
1 . Compound 2 
       
         
           
           
               
               
           
         
       
     
     
         2 . A conjugate comprising a glycosylphosphatidylinositol (GPI) fragment covalently linked to a protein. 
     
     
         3 . The conjugate of  claim 2 , wherein the GPI fragment is compound 2 
       
         
           
           
               
               
           
         
       
     
     
         4 . The conjugate of  claim 2 , wherein the GPI fragment is covalently linked to the protein through a sulfhydryl-maleimide linker. 
     
     
         5 . The conjugate of  claim 4 , wherein the conjugate is 
       
         
           
           
               
               
           
         
       
     
     
         6 . (canceled) 
     
     
         7 . The conjugate of  claim 2 , wherein the protein is albumin. 
     
     
         8 - 12 . (canceled) 
     
     
         13 . A vaccine comprising an immunogenic amount of a conjugate comprising a glycosylphosphatidylinositol (GPI) fragment covalently linked to a protein. 
     
     
         14 . The vaccine of  claim 13 , wherein the GPI fragment is compound 2 
       
         
           
           
               
               
           
         
       
     
     
         15 . The vaccine of  claim 13 , wherein the GPI fragment is covalently linked to the protein through a sulfhydryl-maleimide linker. 
     
     
         16 . The vaccine of  claim 15 , wherein the conjugate is 
       
         
           
           
               
               
           
         
       
     
     
         17 . (canceled) 
     
     
         18 . The vaccine of  claim 13 , wherein the protein is albumin. 
     
     
         19 - 25 . (canceled) 
     
     
         26 . A compound selected from the group consisting of:

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.